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Background: Phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway is a
therapy target of cancer. We aimed to confirm the effect of dual PI3K/mTOR inhibitor NVP-BEZ235 on cell
proliferation and apoptosis in Burkitt lymphoma (BL) cells.
Methods: Two human BL cell lines, CA46 and RAJI were used in this study. The proliferation of BL cells was
detected by manganese tricarbonyl transfer (MTT) assay. Cell cycle and apoptosis assay were examined by flow
cytometric analysis. The phosphorylation levels of AKT (Thr308), AKT (Ser473), and RPS6 were evaluated by western
blot analysis.
Results: NVP-BEZ235 significantly inhibited the proliferation of BL cells (CA46 and RAJI) and the inhibition effect
was time and dose-dependent. Cell cycle analysis indicated that the cells (CA46 and RAJI) were mostly arrested in
G1/G0 phase. Cell apoptosis assay showed that the late apoptotic cells were significantly increased after 72 h treatment
by 100 nmol/L of NVP-BEZ235. In addition, results also found that NVP-BEZ235 reduced the phosphorylation levels of
AKT (Thr308), AKT (Ser473), and PRS6 in BL cells (CA46 and RAJI). Moreover, this inhibition effect on phosphorylation
was dose-dependent.
Conclusions: NVP-BEZ235 effectively inhibited cell proliferation by G0/G1 cell-cycle arrest and induced apoptosis
through deregulating PI3K/Akt/mTOR pathway in BL cells.
Keywords: Burkitt lymphoma, Phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway,
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Burkitt lymphoma (BL), as a highly aggressive non-
Hodgkin lymphoma, drives from germinal center (GC) B
cells [1, 2]. There are three recognized clinical variants
based on the WHO classification: endemic (eBL, found
predominantly in equatorial Africa), sporadic (sBL, the
predominant type found in non-malarial areas), and asso-
ciated with immunodeficiency (including human im-
munodeficiency virus–associated and post-transplantation
lymphoproliferative disorder after solid organ transplant-
ation) [1, 3, 4]. Based on recent reports and statistics, BL
is the most common form of non-Hodgkin lymphoma in* Correspondence: xiongpengzhu@163.com
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creativecommons.org/publicdomain/zero/1.0/children [5, 6] and the incidence is higher in males than in
females [7–9]. Currently, chemotherapy remains the main
treatment modality for BL. However, the acquired che-
moresistance remains a challenging issue and reduces the
possibility of effective salvage and cure [10]. Meanwhile,
the clinical outcome is still poor in patients with over
40 years old [2, 11]. Therefore, a novel and effective treat-
ments are needed to enhance the efficacy of chemotherapy
and improve clinical outcomes in the treatment of BL
patients.
The phosphatidylinositol 3-kinase/Akt/mammalian tar-
get of rapamycin (PI3K/Akt/mTOR) pathway deregulation
is a common event in human cancer and associated with
the tumor cell proliferation, growth and apoptosis [12,
13]. Currently, this pathway has become a favorable
therapy target of cancer [13–15], including BL [16, 17].distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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geting this pathway in the clinical treatment of BL.
Meanwhile, it has been reported that the deregulation
of PI3K/Akt/mTOR pathway can leading to chemoresis-
tance in BL [18]. Thus, it is important to find a novel
drug targeting PI3K/Akt/mTOR pathway for treating
BL.
NVP-BEZ235 is a dual inhibitor of PI3K and mTOR.
It is a synthetic compound belonging to the class of imi-
dazoquinolines, and inhibits PI3K and mTOR catalytic
activity by competitively binding to the ATP-binding
cleft [19]. Previous studies have reported its inhibition in
tumor cell proliferation and growth as well as promotion
in apoptosis in many other cancers [20–22]. Meanwhile,
Shortt et al. [23] reported that NVP-BEZ235 induced
apoptosis of BL cells was associated with the PI3K/Akt/
mTOR pathway in MYC-driven BL cells. However, it is
unknown that whether this effect of NVP-BEZ235 still
exist in BL cells without MYC-driven. Moreover, Shortt
et al. [23] also showed that the BEZ235-induced apop-
tosis occurred independently of p53. Thus, we have per-
formed this study using two BL cell lines (CA46 and
RAJI, which all have mutant p53) to further assess and
confirm the effects of NVP-BEZ235 on BL cells.
Materials and methods
Cell lines and reagents
Two human BL cell lines, CA46 and RAJI, were pur-
chased from KeyGEN Biotech (NanJing, China), and cul-
tured in RPMI 1640 medium which contained 10 %
newborn calf serum (Gibco, Waltham, MA, USA) in a
humidified 37 °C incubator with 5 % CO2.
NVP-BEZ235 was purchased from Selleckchem
(Houston, TX, USA) and dissolved in dimethylsulfox-
ide (DMSO) to a concentration of 10 mmol/L. Before
experiment, NVP-BEZ235 was stored at −20 °C. In the
following experiments, it would be further diluted to
an appropriate final concentration.
Cell proliferation assay
Cells from two cell lines (CA46 and RAJI) were respect-
ively seeded in different 96-well plates with 10 % newborn
calf serum at a density of 1 × 104 cells/well. The cells were
respectively treated with NVP-BEZ235 at different con-
centrations (1, 10, 50, 100, 500 and 1000 nmol/L) for 24,
48, and 72 h. Meanwhile, the cells incubated with equal
volume of DMSO instead of NVP-BEZ235 were used as
control. After incubation period, 3-(4, 5-dimethylthiazolyl-
2)-2, 5-diphenyltetrazolium bromide (MTT, Amresco,
OH, USA) was immediately added to the wells at a final
concentration of 20 μmol/L and the cells were incubated
for 4 h. Subsequently, the cells were collected through
centrifugation. The supernatant was discarded and 150 μl
DMSO was used to suspend the cells in each well. Finally,measurement of absorbance at 490 nm was performed
using an automatic multi-well spectrophotometer
(Bio-Tek Instruments, Vermont, USA). The inhibition
rate was calculated based on the formula: Inhibition
rate (%) = (1 - Absorbance of wells treated with NVP-
BEZ235 /Absorbance of control) × 100.
Cell cycle analysis
Cells from two cell lines were respectively seeded in dif-
ferent 6-well plates with 10 % newborn calf serum at a
density of 1 × 105 cells/ml. The cells were respectively
treated with NVP-BEZ235 at concentrations of 10 and
100 nmol/L for 48 h. Meanwhile, the cells incubated
with equal volume of DMSO instead of NVP-BEZ235
were used as control. After incubation period, cells were
harvested through centrifugation and washed twice with
ice-cold phosphate-buffered saline (PBS). Afterwards,
the cells were fixed using 1 ml ice-cold PBS and 3 ml
ethanol at −20 °C overnight. After fixation, the cells were
washed twice with ice-cold PBS again, and then incubated
with 30 μg/ml of propidium iodide (PI, Sigma-Aldrich, St
Louis, MO) and 40 μg/ml of Rnase (Sigma-Aldrich, St
Louis, MO) for 30 min at room temperature in a dark
room. Before analysis by the FACSCalibur cytometer
(BD Biosciences, San Jose, CA), the cells were separated
through a 200-mesh nylon filter. Data were analyzed
using the Modfit LT software (BD Biosciences, San Jose,
CA).
Cell apoptosis assay
BL cells were seeded in 6-well plates with 10 % newborn
calf serum at a density of 1 × 105 cells/ml. The cells were
respectively treated with 100 nmol/L of NVP-BEZ235
for 48 h and 72 h. Meanwhile, the cells incubated with
equal volume of DMSO instead of NVP-BEZ235 were
used as control. After treatment, cells were washed twice
with ice-cold PBS. Subsequently, apoptosis was assayed
using the FITC Annexin V Apoptosis Detection Kit I
(BD Biosciences, San Jose, CA, USA), following the
manufacturer’s instructions. The cells were assessed
using flow cytometric analysis. Viable cells were FITC
Annexin V and PI -negative cells; cells that were FITC-
Annexin V-positive and PI-negative were considered as
being in early apoptosis; whereas necrotic cells were
FITC-annexin-V negative/low-PI positive; cells that were
both FITC-Annexin V- and PI-positive were considered
as being in late apoptosis;
Western blot analysis
In the PI3K/Akt/mTOR pathway, AKT is the central
key component of this pathway and activated through
phosphorylation at Ser473 and Thr308. Moreover,
ribosomal protein S6 (RPS6) would be phosphorylated
in the downstream of mTOR signaling [13]. Thus, we
Fig. 1 NVP-BEZ235 inhibited the proliferation of Burkitt lymphoma
cells. a CA46; b RAJI
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through western blot analysis to assess if NVP-
BEZ235 could affect the PI3K/Akt/mTOR pathway in
BL cells.
BL cells were seeded in 6-well plates with 10 % newborn
calf serum at a density of 1 × 106 cells/ml. Meanwhile, the
cells were respectively treated with different concentra-
tions of NVP-BEZ235 (1, 10, 100, and 200 nmol/L) for 0,
3, 6,12, 24, and 48 h. The cells incubated with equal vol-
ume of DMSO instead of NVP-BEZ235 were used as con-
trol. Western blotting was performed as described
previously [24]. Briefly, after washing twice by PBS, cells
were lysed with RIPA (Radio Immunoprecipitation Assay)
lysis buffer (Solarbio, Beijing, China), which contained
1 mmol/L PMSF (Phenylmethanesulfonyl fluoride). The
protein concentrations of the cell lysates were determined
using the Enhanced BCA Protein Assay kit (Beyotime,
Haimen, China). Proteins were separated by sodium dode-
cyl sulfate-polyacrylamide (SDS) gel electrophoresis and
then transferred to nylon membranes. The membranes
were blocked in TBS-T buffer solution containing 5 %
non-fat dry milk at 4 °C overnight. Immunoblotting was
performed using rabbit polyclonal antibodies against AKT
(1:100 dilution), phosphorylated Akt (Ser473 or Thr308,
both 1:100 dilution), RPS6 (1:100 dilution), phosphory-
lated RPS6 (1:100 dilution), and β-actin (1:1000 dilution),
respectively. Blots were probed with horseradish per-
oxidase–conjugated secondary antibody (anti-rabbit)
and developed using enhanced chemiluminescence re-
agent (Amersham Biosciences, Piscataway, NJ). All
antibodies were purchased from Bioss (BeiJing, China).
Band density was imaged and the levels of protein ex-
pression quantified using Molecular Imager VersaDoc
MP 4000 system (Bio-Rad) and normalized to the β-
actin levels. The phosphorylation levels of proteins
were assessed based on the ratios of phosphorylated
proteins to the corresponding total proteins.Statistical analysis
The data were presented as means ± SD. Comparison be-
tween groups were performed using a Non-parametric
test or one-way ANOVA. A value of P < 0.05 was con-
sidered statistically significant. Statistical analyses were
performed using SPSS 17.0 software (Chicago, USA).Results
NVP-BEZ235 inhibited BL cell proliferation
As shown in Fig. 1, the inhibition rates of two BL cell
lines were significantly increased with the increasing incu-
bation time and concentration of NVP-BEZ235 (P < 0.05),
indicating that NVP-BEZ235 could inhibit the prolifera-
tion of BL cells and this antiproliferative effect was time
and dose-dependent.G0/G1 phase arrest induced by NVP-BEZ235
NVP-BEZ235 induced cell cycle arrest in G1/G0 phase
in both BL cell lines (Figs. 2 and 3). Compared with con-
trol, cells in the G1/G0 phase were significantly in-
creased (P < 0.05) and in G2/M and S phases were
significantly reduced after 48 h treatment by10 nmol/L
or 100 nmol/L of NVP-BEZ235 (P < 0.05). Moreover,
compared with cells treated with 10 nmol/L NVP-
BEZ235, there were significantly more cells in G1/G0
phase when cells were treated with 100 nmol/L NVP-
BEZ235 (P < 0.05).
Effect of NVP-BEZ235 on cell Apoptosis
Compared with control, the viable cells (FITC Annexin
V and PI negative) were significantly reduced and the early
apoptotic cells (FITC-Annexin V-positive and PI-negative)
were significantly increased by the treatment of 100 nmol/
Fig. 2 NVP-BEZ235 blocked the cell cycle of Burkitt lymphoma cells at the G1/G0 phase. a CA46; b RAJI. * P < 0.05, compared with control;
# P < 0.05, compared with the cells treated with 10 nmol/L NVP-BEZ235
Fig. 3 Cell cycle distribution was analyzed by flow cytometry
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Fig. 4 NVP-BEZ235 induced apoptosis in Burkitt lymphoma cells. a CA46; b RAJI. * P < 0.05, compared with control
Fig. 5 Apoptosis was detected by flow cytometry using Annexin-V and propidium iodide staining methods
Li et al. Cancer Cell International  (2015) 15:65 Page 5 of 9
Li et al. Cancer Cell International  (2015) 15:65 Page 6 of 9L of NVP-BEZ23 for 48 h and 72 h (P < 0.05). Moreover,
although 48 h treatment by 100 nmol/L of NVP-BEZ235
did not cause the significant increase of late apoptotic
cells (FITC Annexin V and PI positive) (P > 0.05), the
late apoptotic cells were significantly increased after
72 h incubation of 100 nmol/L of NVP-BEZ235 (P < 0.05,
Figs. 4 and 5).
Effect of NVP-BEZ235 on PI3K/AKT/mTOR pathway in BL
cells
Figures 6 and 7 showed the western blotting results. The
phosphorylation levels of AKT (Thr308), AKT (Ser473),
and PRS6 were modestly inhibited by NVP-BEZ235 in
both CA46 and RAJI cells (P < 0.05). Moreover, the in-
hibition effect was significantly enhanced with the in-
creasing dose of NVP-BEZ235, indicating this inhibition
effect was dose-dependent (P < 0.05, Fig. 6b). In addition,
the phosphorylation levels of AKT (Ser473) and PRS6Fig. 6 Dose dependent inhibition effect of NVP-BEZ235 on the phosphoryl
cells. a results of western blot; b phosphorylation levels of AKT (Thr308), AKT (
0, 10, 100, and 200 nmol/L for 12 h. * P < 0.05, compared with controlwere also modestly decreased after the cells were incu-
bated with 100 nmol/L of NVP-BEZ235 for 3, 6, 12, 24,
and 48 h. Meanwhile, NVP-BEZ235 also modestly inhib-
ited the phosphorylation of AKT (Thr308) with the in-
cubation time of 3, 6, 12 h (P < 0.05). However, the
phosphorylation level of AKT (Thr308) recovered to
baseline after the cells were treated by 100 nmol/L of
NVP-BEZ235 for 24 and 48 h (P > 0.05). Results indi-
cated that there was no obvious time–dependent inhib-
ition effect of NVP-BEZ235 on the phosphorylation of
AKT (Thr308), AKT (Ser473), and PRS6 (Fig. 7b).
Discussion
New therapeutic strategies are necessary for BL, because
of the resistance of chemotherapy and poor outcomes.
The PI3K/Akt/mTOR pathway is a therapy target of
cancer. In this study, we found that the NVP-BEZ235
(a dual inhibitor of PI3K and mTOR) effectivelyation levels of AKT (Thr308), AKT (Ser473), and PRS6 in Burkitt lymphoma
Ser473), and PRS6 in cells treated with NVP-BEZ235 at concentrations of
Fig. 7 Phosphorylation levels of AKT (Thr308), AKT (Ser473), and PRS6 were significantly changed in the cells treated with 100 nmol/L NVP-BEZ235 for
0 h, 3 h, 6 h, 12 h, 24 h, and 48 h. a results of western blot; b phosphorylation levels of AKT (Thr308), AKT (Ser473), and PRS6 in cells treated with
100 nmol/L NVP-BEZ235 for 0 h, 3 h, 6 h, 12 h, 24 h, and 48 h. * P < 0.05, compared with control
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in two BL cell lines. Also, the cells were mostly arrested
in G1/G0 phase by NVP-BEZ235 in BL cells. Moreover,
the inhibition effect of NVP-BEZ235 on cell proliferation
was time and dose-dependent. In addition, the phos-
phorylation levels of AKT (Thr308), AKT (Ser473), and
PRS6 were also modestly changed by NVP-BEZ235. The
dose-dependent inhibition effect of NVP-BEZ235 was
also found on phosphorylation of AKT (Thr308), AKT
(Ser473), and PRS6. However, this inhibition effect was
not time-dependent.
Similar with other cancers (such as endometrial car-
cinomas [25], human pancreatic cancer [26], thyroid
cancer [27] and osteosarcoma [28]), NVP-BEZ235 also
suppresses cell proliferation by inducing G0/G1 cell-cycle
arrest in BL cells. Meanwhile, significantly decreased
phosphorylation of AKT (Thr308), AKT (Ser473), and
PRS6 in BL cells treated by NVP-BEZ235, indicated thatthe PI3K/Akt/mTOR pathway was deregulated by NVP-
BEZ235 in BL cells. It was reported that BL cells (P493-6)
could be arrested in G0/G1 after the expression of myc
was switched off, which was associated with the inhibition
of a set of cell cycle activators (cyclin D2, cyclin E and
Cdk4) [29]. Moreover, the expression of Cyclin D was
found to be associated with activation of Akt, which was
depended on the phosphorylation of AKT (Thr308) and
AKT (Ser473), in PI3K/Akt/mTOR pathway [30]. In
addition, it was reported that the PI3K/Akt/mTOR path-
way involved Akt-mediated phosphorylation of FoxO
transcription factors, which was required by the Myc-
induced proliferation and transformation [31]. Meanwhile,
down-regulation of Cyclin D involves the cell cycle arrest
induced by FoxO Transcription Factors [32]. Therefore,
the G0/G1 cell-cycle arrest induced by NVP-BEZ235 in
this study might be caused by the inhibition of PI3K/Akt/
mTOR pathway, which could suppress Myc-induced
Li et al. Cancer Cell International  (2015) 15:65 Page 8 of 9proliferation by decreasing the expression of Cyclin D and
phosphorylation of FoxO transcription factors. Besides,
the dose-dependent effect demonstrated that high dose of
NVP-BEZ235 could significantly inhibit the PI3K/Akt/
mTOR pathway than low dose of NVP-BEZ235. The most
appropriate application dose of NVP-BEZ235 need to be
further investigated.
In this study, apoptosis of BL cells was also induced
by NVP-BEZ235. Considering the mutant of p53 in the
two cell lines (CA46 and RAJI), the independently of
p53 in the NVP-BEZ235 induced apoptosis of BL cells
was confirmed, which was in line with the results of
Shortt et al. [23]. However, the mechanism for NVP-
BEZ235 induced apoptosis of BL cells still need more
studies to explore. Previous studies have reported that
the S6 kinase (S6K) play roles in different mechanisms
of apoptosis [33–35]. In PI3K/Akt/mTOR pathway, acti-
vation of mTOR results in the phosphorylation of nu-
merous substrates, including the phosphorylations of S6
kinase (S6K) by mTORC1 [36]. Then the PRS6, as the
substrate of S6K, would be phosphorylated [37]. More-
over, it was reported that the PRS6 was also significantly
associated with apoptosis (such as gamma irradiation-
induced apoptosis, and cisplatin-induced apoptosis) [38,
39]. Thus, we speculated that the effect of NVP-BEZ235
on apoptosis of BL cells may be associated with the
phosphorylation of PRS6 and SK6 may play important
roles in this effect.
However, some limitation should be noted in this
study. Firstly, we have found the inhibition effect of
NVP-BEZ235 on PI3K/Akt/mTOR pathway which was
associated with chemoresistance of BL cells [18]. Never-
theless, we have not concerned on the changes of che-
moresistance by NVP-BEZ235 in BL cells. Further
studies were required to investigate it for further explor-
ing the clinical value of NVP-BEZ235. Secondly, the
time dependent effect of NVP-BEZ235 on inhibiting cell
proliferation was significant, but there was no obvious
time–dependent inhibition effect of NVP-BEZ235 on
the phosphorylation of AKT (Thr308), AKT (Ser473),
and PRS6. Especially for the phosphorylation level of
AKT (Thr308), it recovered to baseline after the cells
were treated by NVP-BEZ235 for 24 h and 48 h. Hence,
the time-dependent effect of NVP-BEZ235 on BL cells de-
mands more investigations and evidences. In addition, be-
cause the FACS staining was just used for assessing the
effect of NVP-BEZ235 on cell cycle in this study, so the
FACS staining after incubating cells with the drug for 72 h
was not performed to verify the effect of NVP-BEZ235 on
apoptosis. Although NVP-BEZ235 induced apoptosis of
BL cells were found by the Annexin V and PI staining
after 72 h treatment by 100 nmol/L of NVP-BEZ235, fur-
ther studies were required to confirm the results of this
study.Conclusions
In conclusion, NVP-BEZ235 might effectively inhibit BL
cells proliferation by G0/G1 cell-cycle arrest through de-
regulating the PI3K/Akt/mTOR pathway, which was asso-
ciated with the suppression of Myc-induced proliferation.
Moreover, the BL cells apoptosis may be induced by NVP-
BEZ235 through decreasing the phosphorylation of PRS6.
This study further confirmed the effect of NVP-BEZ235
on BL cells and provided evidence for the clinical applica-
tion of NVP-BEZ235 on the treatment of BL.
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